Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Subscribe|Follow Us On
Cancer-Driver-Agnostic Targeting of Amplified Surface Proteins Identifies MPZL1 for Selective CAR-T Cell Therapy
[Nature Communications] Researchers developed a monoclonal antibody targeting myelin protein zero–like 1 (MPZL1)’s extracellular domain and engineered CAR-T cells that selectively eliminate MPZL1-positive cancer cells in vitro.
From Cellular Therapy to Biologics: Non-Viral Delivery Strategies for In Vivo CAR-T Engineering
[Critical Reviews in Oncology/Hematology] The authors provide an overview of the key physiological barriers encountered in in vivo CAR-T cell engineering, alongside the corresponding principles of engineered design.
Safety and Efficacy of Allogeneic CD19-Directed CAR-T Therapy CTX110 in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
[Blood Advances] This multicenter, single-arm, Phase I/II study evaluated the safety and efficacy of CD19-directed allogeneic CAR immunotherapy CTX110 in adult patients with relapsed/refractory B cell non-Hodgkin lymphoma.
Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102
[Cancer Immunology Research] In this first-in-human, open-label, Phase I, dose-escalation study, researchers evaluated a single TAK-102 infusion in 11 patients with glypican-3-positive advanced solid tumors refractory or intolerant to standard therapies.
Co-Delivery of Lentiviral Vectors and Cas9-Containing Virus-Like Particles Enables Rapid, Scalable Manufacture of Gene-Edited CAR T Cells
[Molecular Therapy] Investigators reported lentiviral-based virus-like particles that package and deliver Cas9 ribonucleoproteins to primary human T cells. Using distinct pseudotyping strategies for virus-like particles and for lentiviral or γ-retroviral vectors, they achieved CAR expression and targeted gene disruption.
Engineering Next-Generation CAR-T Cells for Glioblastoma Treatment: A Review of Innovations in Receptor Design, Antigen Targeting, and Therapeutic Persistence
[International Immunopharmacology] Researchers evaluated how receptor architecture, antigen selection, multi-antigen targeting, tumor microenvornment- and exhaustion-resistant engineering, locoregional delivery, alternative CAR-cell platforms and computational design address the major biological and anatomical barriers of glioblastoma.
The V Foundation for Cancer Research Awards $1.8 Million in Grants to Children’s Hospital of Philadelphia Researchers
[Children’s Hospital of Philadelphia] Dr. Andrei Thomas-Tikhonenko was awarded the $1 million V Foundation Pediatric All-Star Cancer Research Grant to develop a novel CAR T cell therapy for children with T cell acute lymphoblastic leukemia.
Localized PD-1 CAR T Therapy Reprograms Neuroinflammation
[Cell] Researchers developed PD-1-directed CAR T cells that selectively depleted pathogenic PD-1+ CD4 T cells and locally released IL-10.
Reprogramming Engineered Autologous T Cells to Overcome Resistance in Patients with Merkel Cell Carcinoma
[Science Translational Medicine] Investigators identified T cell receptor (TCR)MCC1, a highly avid, HLA-A*02:01–restricted T cell receptor targeting the Merkel cell polyomavirus oncoprotein large-T antigen15–23.
Ex Vivo Live Macrophage Engineering Strategies in Immunotherapy
[Biotechnology Advances] Successful macrophage immunotherapy requires solving two central in vivo determinants: preserving a therapeutically favorable functional state despite suppressive cues, and achieving robust, disease-selective localization and engagement.
T Cell Immunosenescence Limits CD19 CAR T-Cell Function in Chronic Lymphocytic Leukemia
[Blood] Investigators identified immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in chronic lymphocytic leukemia and a candidate for therapeutic modulation.
Tisa-Cel and Axi-Cel CAR Structure Influences the Development of Resistance to CD19-CAR-T Therapy
[Leukemia] Researcher showed that CAR structure is a critical determinant of CD19 loss in tumor B cells. Specifically, repeated exposure to CD19–4-1BB-based CAR-T cells, but not CD19–CD28-based counterparts, drives FMC63-epitope and total CD19 protein loss.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
